Psoriasis and psoriatic arthritis have been associated with the underreporting and undertreatment of pain. To provide adequate care and management of pain in psoriatic disease, a multidisciplinary approach is required.
The Agency does not believe the data support the safety or efficacy of the treatment either as monotherapy or in combination with other analgesics.
The researchers analyzed the trends in naloxone prescriptions filled during the COVID-19 pandemic in the US and compared these with trends in opioid and overall prescriptions.
The researchers created two new “swear” words and assessed the pain-relieving effects of saying these new words during an ice-water pain challenge.
Researchers sought to determine the neurologic phenotypes, incidence, and outcomes among adults hospitalized with COVID-19.
RCT findings reveal intraoperative caffeine’s potential to reduce opioid consumption and improve recovery after surgery.
Novel 10 zHz spinal cord stimulation system in the treatment of refractory lumbosacral back pain in surgery naïve patients study results.
If immediate-release and extended-release formulations of buprenorphine are similarly efficacious to treat opioid use disorder, is one superior?
Besides acetaminophen, NSAIDs, triptans, ergot alkaloids, and adjunct antiemetics, gepants and ditans are recently approved for migraine patients.
The MAT Act would allow all clinicians with standard controlled medication licenses to prescribe buprenorphine for opioid use disorder.
